Cagrilintide is an amylin analogue that helps regulate appetite. In a randomized trial of over 3400 patients who were overweight or obese and had 1 weight related complication, individuals assigned to a combination 1 CagriSema 2.4 mg 2.4 mg FDA NDA filing; Novo Nordisk data on file., 2 Garvey WT, Blher M, Osorto Contreras CK, et al. Coadministered cagrilintide and semaglutide in adults with overweight or Cagrilintide 3mg, Semaglutide 3mg Blend (SALE!) Polaris Peptides Cagrilintide Research Peptide Information Peptpedia CagriSema obesity drug: what the phase 3 data shows CagriSema's second phase 3 trial demonstrates 15.7% weight loss over 68 weeks. Michael Weintraub, MD